Wound Management Technologies 2012 Sales Strategy Shows Positive Results; Receives Final Resolution with SEC
Forth Worth, Texas, Feb. 5, 2013 /PRNewswire/ -- WOUND MANAGEMENT TECHNOLOGIES (OTCQB: WNDM | WNDM.PK) finished 2012 with fourth quarter customer sales revenues of approximately $440,000 (an increase of 23% over the previous quarter) and annual sales revenues of approximately $1.18M. In May of 2012 the Company announced it had completed a new three-year strategic plan that focuses on CellerateRX® customer sales and that a new surgical product would be introduced in 2012. In October 2012 the Company announced positive results for the new CellerateRX® surgical products. "Clearly our plan and our team's efforts are yielding results," stated Robert H. Lutz, Jr., Chairman and CEO of the company. "We expect the upward sales trend to continue throughout 2013 and beyond."
WNDM announced today that they received final resolution with the Securities and Exchange Commission on January 15, 2013 and that the resolution reflects the settlement announced by the Company on September 28, 2012. "Resolving the matter regarding charges for acts in 2009 has been of the utmost importance to our company," reported Mr. Lutz. "We are pleased to bring this matter to a conclusion which allows us to move forward with focus on our sales and marketing campaign and our capital program."
With the SEC matter closed, the Company is working on procurement of additional capital to fulfill the advancement of additional product distribution and development of expanded products as reflected in the strategic plan.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development. More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Wound Management Technologies Shareholder Information please call 800-205-7719 or visit www.wmgtech.com.
For Further Information:
Shareholder Relations-Communications: 800-205-7719
SOURCE Wound Management Technologies, Inc.